The PORTOS assay could indicate when or when not to offer dose-escalated radiation for localized prostate cancer.

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...